246 related articles for article (PubMed ID: 37733182)
1. Construction of a Novel Disulfidptosis-Related lncRNA Prognostic Signature in Pancreatic Cancer.
Xing F; Qin Y; Xu J; Wang W; Zhang B
Mol Biotechnol; 2023 Sep; ():. PubMed ID: 37733182
[TBL] [Abstract][Full Text] [Related]
2. Construction and Validation of a Reliable Disulfidptosis-Related LncRNAs Signature of the Subtype, Prognostic, and Immune Landscape in Colon Cancer.
Dong X; Liao P; Liu X; Yang Z; Wang Y; Zhong W; Wang B
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629096
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Analysis of Disulfidptosis-Related LncRNAs in Molecular Classification, Immune Microenvironment Characterization and Prognosis of Gastric Cancer.
Kang K; Li X; Peng Y; Zhou Y
Biomedicines; 2023 Nov; 11(12):. PubMed ID: 38137387
[TBL] [Abstract][Full Text] [Related]
4. Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma.
Wang N; Hu Y; Wang S; Xu Q; Jiao X; Wang Y; Yan L; Cao H; Shao F
Sci Rep; 2024 Jan; 14(1):624. PubMed ID: 38182642
[TBL] [Abstract][Full Text] [Related]
5. Disulfidptosis characterizes the tumor microenvironment and predicts immunotherapy sensitivity and prognosis in bladder cancer.
Pan G; Xie H; Xia Y
Heliyon; 2024 Feb; 10(3):e25573. PubMed ID: 38356551
[TBL] [Abstract][Full Text] [Related]
6. Construction of disulfidptosis-related lncRNA signature for predicting the prognosis and immune escape in colon adenocarcinoma.
Chen P; Yu J; Luo Q; Li J; Wang W
BMC Gastroenterol; 2023 Nov; 23(1):382. PubMed ID: 37946148
[TBL] [Abstract][Full Text] [Related]
7. A disulfidptosis-related lncRNA index predicting prognosis and the tumor microenvironment in colorectal cancer.
Xiao L; Yin W; Chen X; Zhang X; Zhang C; Yu Z; Lü M
Sci Rep; 2023 Nov; 13(1):20135. PubMed ID: 37978247
[TBL] [Abstract][Full Text] [Related]
8. Leveraging a disulfidptosis‑related lncRNAs signature for predicting the prognosis and immunotherapy of glioma.
Chen D; Li Q; Xu Y; Wei Y; Li J; Zhu X; Li H; Lu Y; Liu X; Yan D
Cancer Cell Int; 2023 Dec; 23(1):316. PubMed ID: 38066643
[TBL] [Abstract][Full Text] [Related]
9. A novel disulfidptosis-associated expression pattern in breast cancer based on machine learning.
Wang Z; Du X; Lian W; Chen J; Hong C; Li L; Chen D
Front Genet; 2023; 14():1193944. PubMed ID: 37456667
[No Abstract] [Full Text] [Related]
10. A disulfidptosis-related lncRNA signature for predicting prognosis and evaluating the tumor immune microenvironment of lung adenocarcinoma.
Song Z; Cao X; Wang X; Li Y; Zhang W; Wang Y; Chen L
Sci Rep; 2024 Feb; 14(1):4621. PubMed ID: 38409243
[TBL] [Abstract][Full Text] [Related]
11. A novel disulfidptosis-related lncRNAs signature for predicting survival and immune response in hepatocellular carcinoma.
Guo Z; Xie Y; Zhang L; Liu S; Jiang W
Aging (Albany NY); 2024 Jan; 16(1):267-284. PubMed ID: 38180745
[TBL] [Abstract][Full Text] [Related]
12. A disulfidptosis-related lncRNAs signature in hepatocellular carcinoma: prognostic prediction, tumor immune microenvironment and drug susceptibility.
Liu Y; Meng J; Ruan X; Wei F; Zhang F; Qin X
Sci Rep; 2024 Jan; 14(1):746. PubMed ID: 38185671
[TBL] [Abstract][Full Text] [Related]
13. Disulfidptosis-associated long non-coding RNA signature predicts the prognosis, tumor microenvironment, and immunotherapy and chemotherapy options in colon adenocarcinoma.
Xue W; Qiu K; Dong B; Guo D; Fu J; Zhu C; Niu Z
Cancer Cell Int; 2023 Sep; 23(1):218. PubMed ID: 37759294
[TBL] [Abstract][Full Text] [Related]
14. Bioinformatics-based analysis of the relationship between disulfidptosis and prognosis and treatment response in pancreatic cancer.
Xiong Y; Kong X; Mei H; Wang J; Zhou S
Sci Rep; 2023 Dec; 13(1):22218. PubMed ID: 38097783
[TBL] [Abstract][Full Text] [Related]
15. Identification and validation of a disulfidptosis-related genes prognostic signature in lung adenocarcinoma.
Zhang Y; Sun J; Li M; Hou L; Wang Z; Dong H; Xu W; Jiang R; Geng Y; Guan C; Zhu Z; Wang H; Gong Q; Zhang G
Heliyon; 2024 Jan; 10(1):e23502. PubMed ID: 38223725
[TBL] [Abstract][Full Text] [Related]
16. Disulfidptosis-related lncRNA signature reveals immune microenvironment and novel molecular subtyping of stomach adenocarcinoma.
Li J; Xia C; Song Y; Zhang L; Shang W; Xu N; Lu Q; Liang D
Heliyon; 2024 Apr; 10(8):e29005. PubMed ID: 38628708
[TBL] [Abstract][Full Text] [Related]
17. Machine learning-based disulfidptosis-related lncRNA signature predicts prognosis, immune infiltration and drug sensitivity in hepatocellular carcinoma.
Pu L; Sun Y; Pu C; Zhang X; Wang D; Liu X; Guo P; Wang B; Xue L; Sun P
Sci Rep; 2024 Feb; 14(1):4354. PubMed ID: 38388539
[TBL] [Abstract][Full Text] [Related]
18. Construction of a cancer-associated fibroblasts-related long non-coding RNA signature to predict prognosis and immune landscape in pancreatic adenocarcinoma.
Ye Y; Zhao Q; Wu Y; Wang G; Huang Y; Sun W; Zhang M
Front Genet; 2022; 13():989719. PubMed ID: 36212154
[No Abstract] [Full Text] [Related]
19. Disulfidptosis-Associated lncRNAs are Potential Biomarkers for Predicting Immune Response and Prognosis Within Individuals Diagnosed with Hepatocellular Carcinoma.
Wei Q; Hou YC; Mao FF; Feng JK; Wang X; Cheng SQ
Hepat Med; 2023; 15():249-264. PubMed ID: 38162389
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of a disulfidptosis and M2 TAM-related classifier for bladder cancer to explore tumor subtypes, immune landscape and drug treatment.
Ren C; Wang Q; Xu Z; Pan Y; Li Y; Liu X
J Cancer Res Clin Oncol; 2023 Nov; 149(17):15805-15818. PubMed ID: 37668798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
